Virpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, received a written response from the US Food and Drug Administration (“FDA”) in lieu of a meeting regarding its pre-Investigational New Drug (“pre-IND”) application for DSF100 (1.3% diclofenac epolamine) spray,
September 12, 2018
· 3 min read